Abstract
Background: Delivery of pharmacologically active compounds to the lung for systemic effects is well known and recently has entered a new era with several products achieving regulatory approval. This review focuses on the barriers to pulmonary delivery of biologics. Methods: Lessons learned from the development of recently approved products will be reviewed to shed light on the current challenges that are faced when developing biological products for inhaled delivery. Results: The text and tables presented herein consolidate the current data and ongoing research regarding biological, inhaled products. Conclusion: With this basis, we also review the future prospects for pulmonary delivery of biologics for systemic delivery and how the biological and physical barriers may be overcome.
Keywords: Systemic pulmonary delivery, biologics, inhalation devices.
Current Pharmaceutical Design
Title:Inhaled Biologics: From Preclinical to Product Approval
Volume: 22 Issue: 17
Author(s): Kristin Fathe, Silvia Ferrati, Daniel Moraga-Espinoza, Ashkan Yazdi and Hugh D.C. Smyth
Affiliation:
Keywords: Systemic pulmonary delivery, biologics, inhalation devices.
Abstract: Background: Delivery of pharmacologically active compounds to the lung for systemic effects is well known and recently has entered a new era with several products achieving regulatory approval. This review focuses on the barriers to pulmonary delivery of biologics. Methods: Lessons learned from the development of recently approved products will be reviewed to shed light on the current challenges that are faced when developing biological products for inhaled delivery. Results: The text and tables presented herein consolidate the current data and ongoing research regarding biological, inhaled products. Conclusion: With this basis, we also review the future prospects for pulmonary delivery of biologics for systemic delivery and how the biological and physical barriers may be overcome.
Export Options
About this article
Cite this article as:
Fathe Kristin, Ferrati Silvia, Moraga-Espinoza Daniel, Yazdi Ashkan and D.C. Smyth Hugh, Inhaled Biologics: From Preclinical to Product Approval, Current Pharmaceutical Design 2016; 22 (17) . https://dx.doi.org/10.2174/1381612822666160210142910
DOI https://dx.doi.org/10.2174/1381612822666160210142910 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Current Uses of Robotic Surgery for the Treatment of Benign Adnexal Conditions
Current Women`s Health Reviews Biologic Therapy in Inflammatory and Immunomediated Skin Diseases: Safety Profile
Current Drug Safety Endothelium and Oxidative Stress: The Pandora's Box of Cerebral (and Non-Only) Small Vessel Disease?
Current Molecular Medicine Indicators of Cardiovascular Risk in Metabolic Syndrome: Long Term Follow-up in Italian Patients
Current Vascular Pharmacology Pre-Emptive Conditioning of the Ischemic Heart
Cardiovascular & Hematological Agents in Medicinal Chemistry Tumor Growth-Promoting Properties of Macrophage Migration Inhibitory Factor
Current Pharmaceutical Design Nimodipine Reappraised: An Old Drug With a Future
Current Neuropharmacology The Need for an Interdisciplinary Network of Investigations on HHT
Current Pharmaceutical Design ETS Proteins and MMPs: Partners in Invasion and Metastasis
Current Drug Targets Animal Models of Depressive Illness: The Importance of Chronic Drug Treatment
Current Pharmaceutical Design Future Developments in Osteoporosis Therapy
Endocrine, Metabolic & Immune Disorders - Drug Targets The Role of Nutrition During the COVID-19 Pandemic: What We Know
Endocrine, Metabolic & Immune Disorders - Drug Targets Can γH2AX be Used to Personalise Cancer Treatment?
Current Molecular Medicine Current Treatment of Autoimmune Blistering Diseases
Current Drug Discovery Technologies Receptor-Based Design of Cytokine Therapeutics
Current Pharmaceutical Biotechnology Application of Human Placental Villous Tissue Explants to Study ABC Transporter Mediated Efflux of 2,4-Dinitrophenyl-S-Glutathione
Current Pharmaceutical Biotechnology The Therapeutic use of the Zonulin Inhibitor AT-1001 (Larazotide) for a Variety of Acute and Chronic Inflammatory Diseases
Current Medicinal Chemistry Metabolic Functions of Myostatin and GDF11
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Monoclonal Antibodies in the Treatment of Leukemia
Current Molecular Medicine Oxidative Stress and Amyloid Beta Toxicity in Alzheimer’s Disease: Intervention in a Complex Relationship by Antioxidants
Current Medicinal Chemistry